Print this page    •   Back to Web version of article

European Medicines Agency Issues Restricted Indication for d4T (Stavudine)

March/April 2011

The European Medicines Agency has completed a review of Zerit as part of the procedure for the renewal of the medicine's marketing authorisation.

The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the marketing authorisation for Zerit should be renewed but that the use of the medicine should be severely restricted in both adults and children.

In this context:

Source: European Medicines Agency (EMA) (21.02.2011).


Reference

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 February 2011

A questions and answers document referring to this matter can be found in the following link:
www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500102227

Links to external websites are current at time of posting but not maintained.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art62192.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.